| Trial ID: | L6039 |
| Source ID: | NCT00888238
|
| Associated Drug: |
Sitagliptin
|
| Title: |
A Method to Evaluate Glucose-Dependent Insulin Secretion in Healthy Males (MK-0431-179)
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT00888238/results
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: sitagliptin|DRUG: Comparator: Placebo
|
| Outcome Measures: |
Primary: Insulin Secretion Rate (ISR) During 190 - 340 Minutes Post-dose, ISR was estimated by the deconvolution of peripheral C-peptide concentrations using a 2-compartment model that utilizes population C-peptide kinetic parameters., 190 minutes to 340 minutes | Secondary: Glucose Infusion Rate (GIR) During 190 - 340 Minutes Post-dose, Glucose Infusion Rate required to maintain the target glucose level of 160 milligrams / deciliter (mg/dL) ; GIR was normalized to subject's body weight (kg)., 190 minutes to 340 minutes
|
| Sponsor/Collaborators: |
Sponsor: Merck Sharp & Dohme LLC
|
| Gender: |
MALE
|
| Age: |
ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
12
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: DIAGNOSTIC
|
| Start Date: |
2009-05-12
|
| Completion Date: |
2009-07-21
|
| Results First Posted: |
2010-08-03
|
| Last Update Posted: |
2018-06-26
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT00888238
|
